Ehave, Inc. Files for Canadian Stock & OTCQB Exchanges

The Financial TL;DR

Famous for their work in Ketamine and medical cannabis, digital therapeutics delivery company Ehave, Inc. recently announced their application to be listed on the Canadian Stock Exchange (CSE). Likewise, they applied to upgrade their OTC listing to a OTCQB listing. The OTCQB listing is specifically tailored for developing and early-stage companies. Read our article on ketamine therapy in treatment of stroke conditions here.

FULL PRESS RELEASE BELOW

Ehave, Inc. Files to List on the Canadian Stock Exchange and Applies to Upgrade to OTCQB Exchange

MIAMI, Jan. 04, 2021 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions, announced today the Company has applied to OTC Markets to uplist its shares to the OTCQB. The OTCQB offers transparent trading in entrepreneurial and development stage companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. These standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

Ehave has also applied to list its shares on the Canadian Securities Exchange (CSE). The CSE began operations in 2003 and is based in Toronto, Canada. In order to list on the CSE companies must demonstrate that they have liquid assets, or have a viable plan to show they can sustain their operations and achieve their goals. The CSE also requires any company that has not started generating revenue must have a plan outlining how it will develop its business and have the financial resources to carry it out.

Ehave CEO Ben Kaplan said, “Ehave uplisting to the OTCQB and applying for listing on the CSE is a tremendous milestone for our company and exhibits our continued commitment to our shareholders. We believe listing on the OTCQB will provide the Company with increased access to US institutional and retail investors and a broader shareholder base. A CSE listing will provide Ehave and its shareholders and opportunity to introduce our Company to an entirely new investment audience.” Mr. Kaplan continued, “I would like to take this opportunity to wish all of our shareholders a happy and prosperous New Year.”

Additional Ehave Inc. Information

We are truly grateful for the support of EHVVF shareholders! Please join the conversation on our Ehave supporter’s telegram group at https://t.me/EhaveInc.

The company posts important information and updates through weekly videos from the official company YouTube channel https://www.youtube.com/channel/UCnyW1mgMd0qmYkEMq3O6FWA.

Please follow Ehave on Twitter @Ehaveinc1

About Ehave, Inc.

Ehave, Inc. (EHVVF) is a leader in digital therapeutics and developer of KetaDASH, a home delivery platform for patients who have been prescribed Ketamine infusions. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes. The Ehave Telemetry Portal is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insights. The Ehave Infinity Portal offers a powerful machine learning and artificial intelligence platform with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools. Ehave also owns 75.77% of psychedelic company 20/20 Global’s outstanding shares. Additional information on Ehave can be found on the Company’s website at: www.ehave.com.

KetaDASH is a subsidiary of Ehave that provides a home delivery platform for medical practitioners to administer Ketamine intravenously to patients who have been prescribed Ketamine at the patients’ home. Ketamine is currently used to help ease pain and allows sedatives to be effective at lower doses, lessening the amount of potentially addictive pain medication required after certain medical procedures. Ketamine is now being studied as a treatment for major depression, though it has not yet been approved by the FDA to treat depression. The KetaDASH platform includes software, staffing, protocols, and equipment, as well as a smart and intuitive dashboard which will provide clients and medical professionals with detailed insight on how the Ketamine therapy is working. Patients will be able to create a profile, check availability of administering nurses, and schedule appointments. Additional information on KetaDASH can be found on the Company’s website at: www.ketadash.com.

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading “Risk Factors” in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC’s website, http://www.sec.gov.

For Investor Relations, please contact:

Gabe Rodriguez

Phone: (623) 261-9046

Email: [email protected]

Microdose Psychedelic Insights

Microdose Psychedelic Insights

Your Guide to the Business of Psychedelics. Our mission is to shift the world's perception of psychedelic medicine.